On the contrary, in prostate cancer, as AR is still able to bind in the absence of FOXA1, a mutation in FOXA1 which inhibits its DNA binding capacity may not inhibit AR binding, but could instead alter its binding profile and transcriptional targets (Sahu et al., 2011; Wang et al., 2011). Here, AR is linked to Familial prostate cancer.